Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
To assess the safety, tolerability, and immunogenicity of ACC-001, an investigational active
immunization, in patients with mild to moderate Alzheimer's disease.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Collaborator:
Janssen Alzheimer Immunotherapy (JAI) Research and Development, LLC